Welcome to our dedicated page for Oppenheimer Hld news (Ticker: OPY), a resource for investors and traders seeking the latest updates and insights on Oppenheimer Hld stock.
Oppenheimer Holdings Inc. (NYSE: OPY) is a middle market investment bank and full service broker-dealer active in the investment banking and securities industry. Through its subsidiaries, including Oppenheimer & Co. Inc., the firm reports news on retail securities brokerage, institutional sales and trading, investment banking, equity and fixed income research, market-making, trust services, and investment advisory and asset management services.
The OPY news flow frequently includes quarterly earnings releases detailing segment results for Wealth Management and Capital Markets, trends in assets under management, and commentary from management on market conditions. Investors can follow updates on advisory and underwriting activity, equities and fixed income trading volumes, and changes in revenue components such as commissions, advisory fees, and bank deposit sweep income.
Company announcements also highlight capital actions and corporate events, such as the declaration of quarterly and special cash dividends on Class A non-voting and Class B voting common stock, as reported in press releases and related Form 8-K filings. In addition, Oppenheimer regularly reports on senior hires and team expansions across its platform, including appointments in Healthcare Equity Capital Markets, biotech research, public finance investment banking, cash equity sales and trading, and regional wealth management leadership.
Other OPY news items describe the evolution of the firm’s Custody and Prime Services (CAPS) platform and the expansion of its global credit and high yield and distressed businesses in the U.S., Europe, and Asia. For readers tracking OPY, this news page offers a centralized view of earnings updates, strategic hires, platform developments, and capital-related announcements drawn from company press releases and disclosures.
Oppenheimer Holdings (NYSE:OPY) agreed to settle a class-action suit over its 2022–2026 cash sweep program by executing a binding term sheet to pay $70 million into escrow, subject to District Court preliminary and final approval.
The settlement, expected to be funded within ten business days after preliminary approval (which the company expects may take up to 90 days), will cover claims through final approval and is without admission of liability. The company said the reserve for the settlement will significantly impact Q1 2026 earnings reported next week, and the amount is expected to be fully tax deductible. The parties will file for preliminary approval within 60 days of the term sheet.
Oppenheimer (NYSE: OPY) elevated David Fleming to a New York-based leadership role in its Private Client Division, reporting to Ed Harrington, and named Ron Guidi branch manager in San Francisco, effective April 9, 2026. Wealth Management reported >$1 billion revenue in 2025, AUM $55.2 billion, and AUA $143.3 billion as of December 31, 2025. Fleming previously grew the San Francisco branch revenue by 36%, assets by 34%, and added seven advisors since joining in 2022.
Oppenheimer (NYSE: OPY) named Bill Farmer Managing Director and Head of Aerospace & Defense Technology Investment Banking, effective April 8, 2026. Farmer will be based in Baltimore and report to Robin Graham, leading M&A and coordinating equity and debt capital markets for aerospace, defense and government services.
He brings over 25 years of experience and more than 100 completed transactions, joining from Brown Gibbons Lang with prior roles at Stifel, Jefferies and Lazard.
Oppenheimer (NYSE: OPY) on March 31, 2026 announced three managing director hires to expand its municipal capital markets platform. The additions — Matt Davis, Lauren Carter, and Brendan Shanahan — bolster underwriting, sales and trading across competitive and negotiated municipal transactions.
The hires aim to strengthen Public Finance capabilities amid rising infrastructure demand and withdrawals by other market participants, supporting issuers and institutional and individual investors.
Oppenheimer (NYSE:OPY) named Chris DeFalco and John Hyland as Co-Heads of its Equity Capital Markets (ECM) investment banking group, effective March 24, 2026. Both will serve on the firm's Investment Banking Commitment Committee while Peter Bennett shifts to lead Corporate Executive Services to connect Investment Banking and Wealth Management.
DeFalco has completed more than 285 equity and equity-linked offerings and led the firm's SPAC practice; Hyland has led over 200 equity offerings and joined Oppenheimer in 2021.
Oppenheimer (NYSE: OPY) named Eric Nortman Managing Director and Head of Debt Private Placements on March 17, 2026, launching a dedicated Debt Private Placements Group to expand private credit financing solutions for investment banking clients.
Nortman will be based in New York, report to Co-Heads of Investment Banking Rob Lowenthal and Gilbert Dychiao, and work with Fixed Income to execute private debt transactions.
Oppenheimer (NYSE: OPY) appointed Vien Le as Managing Director in its Public Finance Investment Banking Group, effective Feb. 25, 2026. Le will be based in Los Angeles and report to Beth Coolidge, Head of Public Finance.
Le brings 20+ years of municipal finance experience, will focus on California and support clients across the West, and previously served at Stern Brothers, UBS and other firms.
Oppenheimer Holdings (NYSE: OPY) reported record results for Q4 and full-year 2025. Q4 net income $74.4M ($7.08 basic EPS) vs $10.7M last year; Q4 revenue $472.6M (+25.9%). For FY-2025, net income $148.4M ($14.13 basic EPS) and revenue $1.64B (+14.4%).
Strength came from Wealth Management AUM record of $55.2B and a Capital Markets revenue surge driven by investment banking activity. The firm declared a $1.00 special dividend and repurchased shares during 2025.
Oppenheimer Holdings (NYSE: OPY) declared a special cash dividend of $1.00 per share on Class A non-voting and Class B voting common stock, payable January 9, 2026 to shareholders of record at the close of business on December 26, 2025.
The aggregate payment is expected to be approximately $10.5 million, and the company said the special dividend will be funded through its existing cash management activities. Management framed the dividend as recognition of improved operating results and financial position.
Oppenheimer (NYSE: OPY) announced on Dec. 8, 2025 that Kostas Biliouris, Ph.D., joined as Managing Director on its Biotech Research Team, based in New York and reporting to William Bird.
Biliouris previously worked at BMO Capital Markets covering genetic medicines, was a VP in biotech research at Morgan Stanley, and held drug development and product strategy roles at Novartis. His background includes a Ph.D. in biochemical engineering and scientific publications with Biogen, Ionis, Merck, Novartis, and the FDA. The firm said the hire strengthens Oppenheimer's long-standing healthcare and biotech research franchise and expands coverage across genetic medicines and related sectors.